Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic - touchONCOLOGY
touchIN CONVERSATION for touchONCOLOGY
Listen to Prof. John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA) in conversation with Dr Raajit Rampal (Memorial Sloan Kettering Cancer Center, New York, NY, USA) on how to optimize the use of JAK inhibitors for patients with myelofibrosis.
They respond to questions submitted by the HCP audience and provide expert insights on:
The key considerations when selecting a first-line JAK inhibitor
How to best manage side effects associated with JAK inhibitors
The treatment options following failure on a first-line JAK inhibitor
This…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.